National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$23.00
add to cart

Rights & Permissions

topleft topright

Control of Cardiovascular Diseases in Developing Countries: Research, Development, and Institutional Strengthening (1998)
Institute of Medicine (IOM)

Citation Manager

. "4 Current Research and Development in Developing Countries." Control of Cardiovascular Diseases in Developing Countries: Research, Development, and Institutional Strengthening. Washington, DC: The National Academies Press, 1998.

Please select a format:

BibTeX EndNote RefMan


Page
43
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Question 2: What is the total annual amount that your organization has spent for the past 10 years on research and development in support of total disease prevention and treatment in developing countries?

Four organizations responded to this question. Their respective spending on R&D for total disease prevention and treatment in developing countries over the past 10 years amounted to approximately U.S. $4.8 million, $83 million, $123 million, and $2 million.

Question 3: What is the total annual amount that your organization has spent for the past 10 years on research and development in support of CVD prevention and treatment in developing countries?

One of the 15 respondents reported CVD research funding was approximately U.S. $42,000.

Question 4: In view of the emerging epidemic of CVD in developing countries, what is the total amount your organization proposes to spend annually over the next 10 years on R&D in support of CVD prevention and treatment in developing countries?

None of the responses indicated that a commitment had been made at the time to research support for CVD.

Although results of this survey can capture information about grant or contract support, indirect support of capacity building (training on-site or in the donor country or technical assistance provided by donor country professionals) may not be captured.

In summary, relatively little grant or contract funding is currently directed toward the support of CVD prevention and treatment in developing countries, and of this very little supports R&D.

Page
43